MovDisordV3, PascalFrancis, Corpus, bibRecord, 001A83

Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease

Identifieur interne : 001A83 ( PascalFrancis/Corpus ); précédent : 001A82; suivant : 001A84

Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease

Auteurs : Juan Carlos Gomez-Esteban ; Juan Jose Zarranz ; Elena Lezcano ; Fernando Velasco ; Roberto Ciordia ; Idoia Rouco ; Jose Losada ; Iker Bilbao

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0393861

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Trouble sommeil, Sommeil, Traitement, Homme, Lévodopa.

English descriptors

KwdEn :
- Human, Levodopa, Nervous system diseases, Parkinson disease, Sleep, Sleep disorder, Treatment.

Abstract

The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 ± 8.2 years, and duration of disease was 7.4 ± 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 ± 19.75 and on the UPDRS III scale was 25.24 ± 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease`
A11	`01`	`1`		`@1 GOMEZ-ESTEBAN (Juan Carlos)`
A11	`02`	`1`		`@1 ZARRANZ (Juan Jose)`
A11	`03`	`1`		`@1 LEZCANO (Elena)`
A11	`04`	`1`		`@1 VELASCO (Fernando)`
A11	`05`	`1`		`@1 CIORDIA (Roberto)`
A11	`06`	`1`		`@1 ROUCO (Idoia)`
A11	`07`	`1`		`@1 LOSADA (Jose)`
A11	`08`	`1`		`@1 BILBAO (Iker)`
A14	`01`			`@1 Neurology Service, Movement Disorders Unit, Cruces Hospital @2 Baracaldo @3 ESP`
A14	`02`			`@1 Neurosciences Department, University of the Basque Country @2 Vizcaya @3 ESP`
A20				`@1 983-988`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000133412770160`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 06-0393861`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 ± 8.2 years, and duration of disease was 7.4 ± 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 ± 19.75 and on the UPDRS III scale was 25.24 ± 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Trouble sommeil @5 03`
C03	`03`	`X`	`ENG`	`@0 Sleep disorder @5 03`
C03	`03`	`X`	`SPA`	`@0 Trastorno sueño @5 03`
C03	`04`	`X`	`FRE`	`@0 Sommeil @5 09`
C03	`04`	`X`	`ENG`	`@0 Sleep @5 09`
C03	`04`	`X`	`SPA`	`@0 Sueño @5 09`
C03	`05`	`X`	`FRE`	`@0 Traitement @5 10`
C03	`05`	`X`	`ENG`	`@0 Treatment @5 10`
C03	`05`	`X`	`SPA`	`@0 Tratamiento @5 10`
C03	`06`	`X`	`FRE`	`@0 Homme @5 11`
C03	`06`	`X`	`ENG`	`@0 Human @5 11`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`07`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 12`
C03	`07`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 12`
C03	`07`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 12`
C07	`01`	`X`	`FRE`	`@0 Cycle veille sommeil @5 37`
C07	`01`	`X`	`ENG`	`@0 Sleep wake cycle @5 37`
C07	`01`	`X`	`SPA`	`@0 Ciclo sueño vigilia @5 37`
C07	`02`	`X`	`FRE`	`@0 Encéphale pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 42`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 42`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 42`
N21				`@1 261`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0393861 INIST
ET :	Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease
AU :	GOMEZ-ESTEBAN (Juan Carlos); ZARRANZ (Juan Jose); LEZCANO (Elena); VELASCO (Fernando); CIORDIA (Roberto); ROUCO (Idoia); LOSADA (Jose); BILBAO (Iker)
AF :	Neurology Service, Movement Disorders Unit, Cruces Hospital/Baracaldo/Espagne; Neurosciences Department, University of the Basque Country/Vizcaya/Espagne
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 7; Pp. 983-988; Bibl. 26 ref.
LA :	Anglais
EA :	The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 ± 8.2 years, and duration of disease was 7.4 ± 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 ± 19.75 and on the UPDRS III scale was 25.24 ± 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.
CC :	002B17; 002B17G; 002B17F
FD :	Système nerveux pathologie; Parkinson maladie; Trouble sommeil; Sommeil; Traitement; Homme; Lévodopa
FG :	Cycle veille sommeil; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble neurologique
ED :	Nervous system diseases; Parkinson disease; Sleep disorder; Sleep; Treatment; Human; Levodopa
EG :	Sleep wake cycle; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Neurological disorder
SD :	Sistema nervioso patología; Parkinson enfermedad; Trastorno sueño; Sueño; Tratamiento; Hombre; Levodopa
LO :	INIST-20953.354000133412770160
ID :	06-0393861

Links to Exploration step

Pascal:06-0393861

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease</title>
<author><name sortKey="Gomez Esteban, Juan Carlos" sort="Gomez Esteban, Juan Carlos" uniqKey="Gomez Esteban J" first="Juan Carlos" last="Gomez-Esteban">Juan Carlos Gomez-Esteban</name>
<affiliation><inist:fA14 i1="01"><s1>Neurology Service, Movement Disorders Unit, Cruces Hospital</s1>
<s2>Baracaldo</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Neurosciences Department, University of the Basque Country</s1>
<s2>Vizcaya</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zarranz, Juan Jose" sort="Zarranz, Juan Jose" uniqKey="Zarranz J" first="Juan Jose" last="Zarranz">Juan Jose Zarranz</name>
</author>
<author><name sortKey="Lezcano, Elena" sort="Lezcano, Elena" uniqKey="Lezcano E" first="Elena" last="Lezcano">Elena Lezcano</name>
</author>
<author><name sortKey="Velasco, Fernando" sort="Velasco, Fernando" uniqKey="Velasco F" first="Fernando" last="Velasco">Fernando Velasco</name>
</author>
<author><name sortKey="Ciordia, Roberto" sort="Ciordia, Roberto" uniqKey="Ciordia R" first="Roberto" last="Ciordia">Roberto Ciordia</name>
</author>
<author><name sortKey="Rouco, Idoia" sort="Rouco, Idoia" uniqKey="Rouco I" first="Idoia" last="Rouco">Idoia Rouco</name>
</author>
<author><name sortKey="Losada, Jose" sort="Losada, Jose" uniqKey="Losada J" first="Jose" last="Losada">Jose Losada</name>
</author>
<author><name sortKey="Bilbao, Iker" sort="Bilbao, Iker" uniqKey="Bilbao I" first="Iker" last="Bilbao">Iker Bilbao</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0393861</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0393861 INIST</idno>
<idno type="RBID">Pascal:06-0393861</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease</title>
<author><name sortKey="Gomez Esteban, Juan Carlos" sort="Gomez Esteban, Juan Carlos" uniqKey="Gomez Esteban J" first="Juan Carlos" last="Gomez-Esteban">Juan Carlos Gomez-Esteban</name>
<affiliation><inist:fA14 i1="01"><s1>Neurology Service, Movement Disorders Unit, Cruces Hospital</s1>
<s2>Baracaldo</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Neurosciences Department, University of the Basque Country</s1>
<s2>Vizcaya</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zarranz, Juan Jose" sort="Zarranz, Juan Jose" uniqKey="Zarranz J" first="Juan Jose" last="Zarranz">Juan Jose Zarranz</name>
</author>
<author><name sortKey="Lezcano, Elena" sort="Lezcano, Elena" uniqKey="Lezcano E" first="Elena" last="Lezcano">Elena Lezcano</name>
</author>
<author><name sortKey="Velasco, Fernando" sort="Velasco, Fernando" uniqKey="Velasco F" first="Fernando" last="Velasco">Fernando Velasco</name>
</author>
<author><name sortKey="Ciordia, Roberto" sort="Ciordia, Roberto" uniqKey="Ciordia R" first="Roberto" last="Ciordia">Roberto Ciordia</name>
</author>
<author><name sortKey="Rouco, Idoia" sort="Rouco, Idoia" uniqKey="Rouco I" first="Idoia" last="Rouco">Idoia Rouco</name>
</author>
<author><name sortKey="Losada, Jose" sort="Losada, Jose" uniqKey="Losada J" first="Jose" last="Losada">Jose Losada</name>
</author>
<author><name sortKey="Bilbao, Iker" sort="Bilbao, Iker" uniqKey="Bilbao I" first="Iker" last="Bilbao">Iker Bilbao</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Sleep</term>
<term>Sleep disorder</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Trouble sommeil</term>
<term>Sommeil</term>
<term>Traitement</term>
<term>Homme</term>
<term>Lévodopa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 ± 8.2 years, and duration of disease was 7.4 ± 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 ± 19.75 and on the UPDRS III scale was 25.24 ± 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GOMEZ-ESTEBAN (Juan Carlos)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ZARRANZ (Juan Jose)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LEZCANO (Elena)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VELASCO (Fernando)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CIORDIA (Roberto)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ROUCO (Idoia)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LOSADA (Jose)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BILBAO (Iker)</s1>
</fA11>
<fA14 i1="01"><s1>Neurology Service, Movement Disorders Unit, Cruces Hospital</s1>
<s2>Baracaldo</s2>
<s3>ESP</s3>
</fA14>
<fA14 i1="02"><s1>Neurosciences Department, University of the Basque Country</s1>
<s2>Vizcaya</s2>
<s3>ESP</s3>
</fA14>
<fA20><s1>983-988</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000133412770160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0393861</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 ± 8.2 years, and duration of disease was 7.4 ± 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 ± 19.75 and on the UPDRS III scale was 25.24 ± 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Trouble sommeil</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Sleep disorder</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trastorno sueño</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sommeil</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Sleep</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sueño</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Cycle veille sommeil</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Sleep wake cycle</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Ciclo sueño vigilia</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>42</s5>
</fC07>
<fN21><s1>261</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0393861 INIST</NO>
<ET>Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease</ET>
<AU>GOMEZ-ESTEBAN (Juan Carlos); ZARRANZ (Juan Jose); LEZCANO (Elena); VELASCO (Fernando); CIORDIA (Roberto); ROUCO (Idoia); LOSADA (Jose); BILBAO (Iker)</AU>
<AF>Neurology Service, Movement Disorders Unit, Cruces Hospital/Baracaldo/Espagne; Neurosciences Department, University of the Basque Country/Vizcaya/Espagne</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 7; Pp. 983-988; Bibl. 26 ref.</SO>
<LA>Anglais</LA>
<EA>The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 ± 8.2 years, and duration of disease was 7.4 ± 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 ± 19.75 and on the UPDRS III scale was 25.24 ± 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.</EA>
<CC>002B17; 002B17G; 002B17F</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Trouble sommeil; Sommeil; Traitement; Homme; Lévodopa</FD>
<FG>Cycle veille sommeil; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble neurologique</FG>
<ED>Nervous system diseases; Parkinson disease; Sleep disorder; Sleep; Treatment; Human; Levodopa</ED>
<EG>Sleep wake cycle; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Neurological disorder</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Trastorno sueño; Sueño; Tratamiento; Hombre; Levodopa</SD>
<LO>INIST-20953.354000133412770160</LO>
<ID>06-0393861</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A83 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0393861
   |texte=   Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease

Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri